Abstract | BACKGROUND: PATIENTS AND METHODS: We retrospectively investigated the clinicopathological data of 461 stage I-III CRC patients. We divided the patients into those who took an ACEI and/or ARB (the ACEI/ARB+ group) and those who did not (the ACEI/ARB- group), and we compared the two groups' recurrence-free survival (RFS) using a Kaplan-Meier curve analysis and log rank test. We also examined the impact of AGTR1 expression on tumor recurrence, using two public CRC datasets. RESULTS: The Kaplan-Meier curves showed a trend toward improved RFS in the ACEI/ARB+ group versus the ACEI/ARB- group (p = 0.063). Subgroup analyses demonstrated that the RFS was significantly better in the ACEI/ARB+ group versus the ACEI/ARB- group in the patients with left-sided CRC (p = 0.030) and those with stage I CRC (p = 0.009). Consistent with these findings, the AGTR1 expression was higher in the left-sided versus right-sided colon (p = 0.048). High AGTR1 expression levels were associated with poor RFS in the GSE39582 dataset's stage I-III CRC patients (p < 0.001), and this finding was also validated in the GSE17536 dataset (p = 0.023). CONCLUSION: ACEI/ARB treatment may reduce tumor recurrence in left-sided CRC and early-stage CRC.
|
Authors | Tsuyoshi Ozawa, Yojiro Hashiguchi, Takahiro Yagi, Yoshihisa Fukushima, Ryu Shimada, Tamuro Hayama, Takeshi Tsuchiya, Keijiro Nozawa, Hisae Iinuma, Soichiro Ishihara, Keiji Matsuda |
Journal | International journal of colorectal disease
(Int J Colorectal Dis)
Vol. 34
Issue 10
Pg. 1731-1739
(Oct 2019)
ISSN: 1432-1262 [Electronic] Germany |
PMID | 31478086
(Publication Type: Journal Article)
|
Chemical References |
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors
|
Topics |
- Aged
- Angiotensin Receptor Antagonists
(therapeutic use)
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Cohort Studies
- Colon
(pathology)
- Colorectal Neoplasms
(drug therapy, pathology)
- Databases as Topic
- Disease-Free Survival
- Female
- Humans
- Male
- Multivariate Analysis
- Neoplasm Recurrence, Local
(drug therapy, pathology)
- Proportional Hazards Models
- Up-Regulation
|